Phase III registered clinical trial results of CM310 showed ...

Phase III registered clinical trial results of CM310 showed significant efficacy superior to the placebo group, including improvements in the area and severity index of eczema, increases in researchers' overall scoring scores, and improvements in pruritus control and quality of life. This may have a positive impact on Conoa-B's stock price.